Daiichi shuffles R&D programs in global restructuring

As part of its global restructuring of R&D, Japan's Daiichi Sankyo is transferring six discovery programs for inflammatory and infectious diseases to India, where it has crafted a new research division around a research team of 170 scientists drawn from Ranbaxy Laboratories. Daiichi's acquisition of Ranbaxy last year has allowed the pharma company to base one of its four R&D centers in India. The other three are Daiichi Sankyo RD Associe in Japan, the U.S.-based Asubio Pharma and U3 Pharma in Germany. Report